Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
Mazza GL, Petersen MM, Ginos B, Langlais BT, Heon N, Gounder MM, Mahoney MR, Zoroufy AJ, Schwartz GK, Rogak LJ, Thanarajasingam G, Basch E, Dueck AC. Mazza GL, et al. Among authors: ginos b. Qual Life Res. 2022 Apr;31(4):1081. doi: 10.1007/s11136-021-03000-2. Qual Life Res. 2022. PMID: 34635962 Free PMC article. No abstract available.
Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.
Jain T, Dueck AC, Kosiorek HE, Ginos BF, Mayo A, Reeder CB, Chesi M, Mikhael J, Keith Stewart A, Leif Bergsagel P, Fonseca R. Jain T, et al. Among authors: ginos bf. Am J Hematol. 2016 Dec;91(12):E504-E505. doi: 10.1002/ajh.24548. Epub 2016 Oct 11. Am J Hematol. 2016. PMID: 27581088 Free article. Clinical Trial. No abstract available.
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, Witzig TE, Ansell SM, Reeder CB. Sonbol MB, et al. Among authors: ginos bf. Leuk Lymphoma. 2018 Sep;59(9):2128-2134. doi: 10.1080/10428194.2017.1416368. Epub 2018 Jan 10. Leuk Lymphoma. 2018. PMID: 29320913 Clinical Trial.
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C. Padrnos L, et al. Among authors: ginos bf. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30104176 Clinical Trial.
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D. Basch E, et al. Among authors: ginos b. J Clin Oncol. 2018 Sep 11;36(31):JCO2018788620. doi: 10.1200/JCO.2018.78.8620. Online ahead of print. J Clin Oncol. 2018. PMID: 30204536 Free PMC article.
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.
Basch E, Stover AM, Schrag D, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears PA, Jonsson M, Bennett AV, Mody G, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Kottschade LA, Charlot M, Weiss A, Bruner D, Dueck AC. Basch E, et al. Among authors: ginos b. JCO Clin Cancer Inform. 2020 Oct;4:947-957. doi: 10.1200/CCI.20.00081. JCO Clin Cancer Inform. 2020. PMID: 33112661 Free PMC article.
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
Mazza GL, Petersen MM, Ginos B, Langlais BT, Heon N, Gounder MM, Mahoney MR, Zoroufy AJ, Schwartz GK, Rogak LJ, Thanarajasingam G, Basch E, Dueck AC. Mazza GL, et al. Among authors: ginos b. Qual Life Res. 2022 Apr;31(4):1069-1080. doi: 10.1007/s11136-021-02968-1. Epub 2021 Aug 21. Qual Life Res. 2022. PMID: 34420143 Free PMC article.
Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).
Mody GN, Stover AM, Wang M, King-Kallimanis BL, Jansen J, Henson S, Chung AE, Jonsson M, Bennett A, Smith AB, Wood WA, Deal A, Ginos B, Dueck AC, Schrag D, Basch E. Mody GN, et al. Among authors: ginos b. Lung Cancer. 2021 Dec;162:1-8. doi: 10.1016/j.lungcan.2021.09.020. Epub 2021 Sep 30. Lung Cancer. 2021. PMID: 34634754
33 results